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Abstract
Chronic obstructive pulmonary disease is prevalent condition commonly associated with cardiovascular diseases.
When both are combined the prognosis of the patient worsens. One cornerstone therapy for most cardiac diseases
is beta-blockade, however concerns about its potential harmful effects on airways function often restrains their use
in patients with COPD and coexistent cardiac diseases. While selective beta1 adrenergic blockers seem to have a
better safety profile, other non-selective beta-blockers can be securely utilized in stable COPD patients with no or
little reactivity when they are indispensable and used with caution.
Evidence provided by post hoc analysis of clinical trials and large observational studies suggests a beneficial effect
of beta-blockers on mortality and exacerbations in mild to moderate COPD patients. Benefits are less obvious in
severe COPD.
Studies on the actual use of beta-blockers suggest that many cardiac patients with COPD (or vice versa) who can
benefit from beta-blocker utilization do not receive such medication as it is recommended in the guidelines
because of die-hard, not justified in most cases, concerns on safety.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a
prevalent condition affecting 6–10 % of the general
population and 11–18 % of the individuals older than
65 years [1]. Many patients with COPD have concomi-
tant heart illnesses susceptible of treatment with beta-
blocker agents (BB). In population studies, the preva-
lence of heart failure (HF) [2–9], coronary artery disease
[2–5, 10–13] and arterial hypertension [2, 4, 11, 12],
double those of the healthy control population and are
usually higher than 20 %. In fact, at least one of these
heart conditions is present in 25–35 % of the patients with
COPD [2, 5, 6, 11, 14]. Moreover, supraventricular ar-
rhythmias —in some cases also susceptible to treatment
with BB— are frequent in COPD as well [2–4, 15, 16].
Cardiovascular comorbidities occur even at the early
stages of COPD, as it was shown in the Atherosclerosis
Risk in Communities Study and the Cardiovascular Health
Study, in which the risk of cardiovascular disease, hyper-
tension and diabetes was already increased in patients
with chronic bronchitis without pulmonary function ab-
normalities yet (Global Initiative for Chronic Obstructive
Lung Disease stage 0) [11].
There is very strong, high quality, evidence demonstrat-
ing increased survival in patient with HF [16–19] and CAD
[20] with BB therapy; nonetheless it is not unusual for phy-
sicians to consider COPD as contraindication to the use of
BB [21] mainly because of concerns that they might induce
bronchospasm and worsen lung function [22–25].
In this article, we will review the evidence for the ben-
efits and safety of use of BB’s in individuals with COPD
and coexistent cardiovascular diseases.
Review
Impact of cardiovascular disease in copd outcomes
Cardiac comorbidity has a substantial impact on the
survival of COPD. In an observational study of 5648
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patients with COPD, cardiovascular morbidity and
mortality was approximately two times higher than in
historical controls without COPD [26]. The most
common cause of cardiovascular morbidity and mor-
tality was HF secondary to CAD [26]. In the towards
a revolution in COPD health (TORCH®)[ 26] study,
heart diseases accounted for 27 % of the deaths
—second after respiratory processes [26] — which is
a remarkable number considering that patients with
known serious heart disease were excluded from the
trial. In the Lung Health Study, a study of smoking
intervention with medical advice and nicotine replace-
ment therapy, in which more than 5900 patients with
relatively mild COPD were followed for about
15 years, 30 % of the deaths were due to either HF
or CAD [27]. A retrospective study of the 11,493
COPD patients included in the health care databases
maintained by the government of Saskatchewan,
Canada during 1997–2000, reported one and half to
four-fold increase in 3-year risk of cardiovascular
death for different causes [overall relative risk (RR)
for all cardiovascular causes = 2.1, 95 % confidence
interval 1.8–2.4] compared with age- and sex-matched
controls without COPD [3].
Cardiovascular events are common during exacerba-
tions and are associated with increased risk of death.
Troponin elevation takes place in a large number of
patients (18–27 %) [28] undergoing COPD exacerba-
tions requiring hospitalization [29–31]. This elevation
is an independent predictor of mortality both during
the exacerbation episode [29] and o,-term [30]. Ven-
tricular arrhythmias and atrial fibrillation were inde-
pendent predictors of mortality in a cohort of 580
patients having COPD as primary disease who were
hospitalized in the respiratory unit of a university
hospital from 1981 to 1990 [Odds ratio (OR) = 1.91,
1.10–3.31 and 2.27, 1.14–4.51, respectively] [32]. Sev-
eral studies aimed to measure the incidence of left
ventricular dysfunction in COPD exacerbations found
a significant association between elevated brain natri-
uretic peptide or N-terminal fragment proNT-pro
brain natriuretic peptide and increased cardiovascular
mortality [33–36]
Cardiovascular disease also leads to hospitalization
of COPD patients, left ventricular dysfunction may be
present in more than 30 % of acute dyspnea episodes
in COPD patients attended at the emergency room or
admitted to the hospital [33, 35–37]. In the Lung
Health Study [27] cardiovascular causes accounted for
42 % of first hospitalizations and 44 % of second hos-
pitalizations, while respiratory causes accounted for
only 14 % of admissions [27]. Raised troponin levels
during an acute COPD exacerbation appears to in-
crease the risk of further admissions [34, 36]
Impact of copd on cardiovascular diseases outcome
From the cardiac perspective there is strong epidemio-
logical evidence showing that the forced expiratory vol-
ume in the first second [38] (FEV1) is a marker for
cardiovascular mortality [39–45]. It has been estimated
that for every 10 % decrease in FEV1, cardiovascular
mortality increases by 28 % and non-fatal coronary
events by almost 20 % [39]. In the cohort of the North-
ern California Kaiser Permanente Medical Care Program
(n = 45,966), COPD was an independent predictor of
cardiovascular hospitalization and mortality over an
average follow-up time of nearly 3 years [46]. In database
of the Worcester Heart Failure Study (a population-
based investigation that includes residents of the Wor-
cester, Massachusetts, metropolitan area) 9748 patients
were hospitalized with acute decompensation of HF dur-
ing the years 1995, 2000, 2002 and 2004. Among those
who survived to hospital discharge, patients with COPD
had a significantly higher risk of death along the next
year than patients who had no previous diagnosis of
COPD (RR = 1.10, 1.06–1.14) [47]. Among 4284 con-
secutive patients who underwent percutaneous coronary
intervention in three tertiary medical centers in New
York City between 1998 and 1999, 3-year mortality was
21 % for patients diagnosed with COPD (n = 183,
4.3 %) versus 9 % in those without COPD (p < 0.001)
[48]. Furthermore, with a hazard ratio (HR) >2 (HR =
2.1, 1.5–3.0, p < 0.001), COPD was the strongest pre-
dictor of late mortality in the Cox proportional-
hazard model after adjustment for demographic, clin-
ical, and angiographic differences [48]. In one study
of 860 patients with COPD and 10,048 without
COPD of the National Heart Lung and Blood Insti-
tute, COPD was associated with higher mortality rates
and repeat revascularization within 1 year after a per-
cutaneous coronary intervention (HR 1.30, 1.01–1.67)
[49]. Interestingly, in this study the higher proportion
of adverse outcomes was associated with lower rates
of use of BB [49].
Beta-blockers
Beta-adrenoceptors (B-ARs) are situated throughout the
cardiac sarcolemma and bronchial and vascular smooth
muscles [50, 51]. While a majority of the B-ARs of
myocardium are of the beta1 type (B1-ARs), a consid-
erable proportion (20 %–25 %) are beta2-adrenorecep-
tos (B2-ARs) [50, 51], however this quantity increases
up to 40 % in the failing heart [28], likely as result of
the selective downregulation of B1-ARs observed in
HF with little or no change in B2-ARs [28]. Both types of
B-ARs of the myocardium, if activated, have a positive ino-
tropic effect [50, 51]. B-ARs in the bronchial and vascular
smooth muscle are mostly B2-ARs and when stimulated
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cause broncho- and vaso-dilatation [22, 24, 50, 51]. There
is a third type of B-ARs (beta3), which role is not yet fully
understood [52].
Beta-blockers are drugs capable of blocking B-ARs
with little or no agonist effect and when administered
reduce myocardial contractility at least in the short term
[53]. Because of this, the use of BB was once thought to
be contraindicated in patients with systolic dysfunction.
Paradoxically, though, some BB’s have proven striking
morbidity and mortality benefits in the management of
patients with cardiac diseases [19, 20, 54–65] and cur-
rently they are considered standard therapy for hyper-
tension, angina, post myocardial infarction, some
tachyarrhythmias and congestive HF [17, 66].
BB’s have several ancillary properties (i.e., partial agonism,
cardioselectivity, membrane stabilizing effect, lipophilicity/
hydrophility, vasodilating actions and inverse antagonism)
than need to be taken into account when selecting them
for the treatment of heart diseases [67, 68]. Some of them
can be relevant when treating patients with COPD.
Selectivity
Beta-blockers are classified into three generations
(Table 1) [50, 51, 60]. The first generation agents (such
as propranolol, sotalol, timolol, and nadolol) are non-
selective and block B1-ARs and B2-ARs. The second-
generation agents are the cardio-selective agents (such
as acebutolol, atenolol, bisoprolol, celiprolol, and meto-
prolol). The third generation agents have vasodilatory
properties [50, 51] mediated either by nitric oxide re-
lease, i.e. nebivolol or carvedilol [52], by added alpha-
adrenergic blockade as in labetolol and carvedilol [52].
The blockage of B2-ARs can cause smooth muscle
contraction and hence bronchospasm in predisposed in-
dividuals [50, 51]. Cardio-selective BB’s have less impact
on lung function and symptoms and preserve, in differ-
ent magnitude, the bronchodilator effect of B2-ARs ago-
nists (see below) [50, 51]; however, it should be borne in
mind that while cardio-selective BB mainly block B1-
ARs, at high doses they are able to block B2-ARs as well
and can adversely affect the airways [50, 51]. Therefore,
the classification into ‘cardio-selective’ BB’s and non-
selective BB’s is important, but oversimplified.
Intrinsic sympathomimetic activity
The therapeutic importance of intrinsic sympatho-
mimetic activity (ISA) in COPD patients is questionable.
Apparently, ISA is able to partially offset the increase in
airway resistance that results from beta-blockade both at
rest and during exertion [69], however no differences
were observed among the non-selective BB’s pindolol
—an agent with ISA— and propranolol, oxprenolol and
timolol —without ISA— in the reduction of FEV1 and
the complete inhibition the bronchodilator response to
inhaled isoprenaline [70]. On the contrary with the
cardio-selective BB’s atenolol and metoprolol the effect
on FEV1 was less pronounced and some bronchodilator
effect remained [70]. There is also evidence suggesting
that BB’s with ISA lead to a downregulation of B2-ARs
[71]. This finding is consistent with the observation that
BB’s with ISA do not produce the long-term increase in
B2-agonist response seen with other BB’s [51]. Since
agents with ISA offer less cardio-protection than BB’s
without this property, these drugs are not recommend-
able in COPD patients with cardiac diseases.
Inverse agonist activity
BB’s do not simply block the receptor, but may further
inactivate receptor activity beyond its baseline value (i.e.,
they decrease the constitutive spontaneous activity of
the receptor in the absence of agonist) [72]. This effect,
called inverse agonist activity, is independent of the B-
AR selectivity and thus the of B1-ARsselective metopro-
lol and bisoprolol have (modest) inverse activity [53, 67]
as well as some non-selective BB such as timolol, pro-
pranolol or nadolol [53, 67], whereas carvedilol shows
no inverse activity [53, 72].
Inverse agonist activity is important when B-ARs are
downregulated because of chronic sympathetic activa-
tion, as occur in chronic HF [51, 53, 73]. In animal





















• Nevibololhowever no differences were observed among the non-
selective
Puente-Maestu et al. COPD Research and Practice  (2015) 1:11 Page 3 of 10
models of asthma, BB’s with inverse agonist activity sig-
nificantly increased B-ARs density in lung membranes
[73] and with time were able to reverse the attenuation
of the effect of salbutamol in airway relaxation induced
by chronic HF [53]. These effects have been also docu-
mented in humans with mild asthma in whom chronic
treatment with nadolol, a BB with Inverse agonist activ-
ity, enhanced the bronchodilator response to salbutamol
over time [22].
Safety of BB in COPD
Selective beta1 adrenergic blockade
There are reports that in some predisposed patients BB,
especially the non-selective ones, are able to trigger
bronchospasm [74–78]; however several small studies of
single-dose treatment or treatment for periods ranging
from 2 days to 12 weeks provide prospective evidence
demonstrating the short term safety of cardio-selective
BB in COPD [79–81]. Long-term prospective evidence is
scarcer. In one small study (n = 27) that examined the
use of bisoprolol in patients with both HF and COPD a
significant reduction in FEV1 was observed at 4 months
(−70 vs +120 ml in the non-beta-blocker group p < 0.01),
however symptoms and quality of life were not altered
[82]. Metoprolol was well tolerated for 3 months by 50
patients with coexistent CAD and mild to severe COPD.
Patients remained free of adverse respiratory effects and
FEV1 was unchanged [83]. In a randomized, double-
blind, crossover trial, 40 CAD patients with mild COPD
and significant reversibility received either bisoprolol
5 mg or atenolol 50 mg [84]. FEV1 declined significantly
(~0.2 l) over 6 months in both treatment arms. Although
lacking a concurrent placebo group, lung function pa-
rameters normalized during the placebo washout pe-
riods, suggesting beta-blockade could have caused
bronchoconstriction [84].
Selective beta1-blockade does not attenuate the bron-
chodilation induced by beta2 agonists [24, 79, 81, 85].
Non-selective BB combined with alpha-blockade
The acute administration of labetalol at maximal dose
did not affected FEV1 in 11 hypertensive patients with
mild to moderate COPD [86, 60]. In a retrospective ana-
lysis of the tolerance to carvedilol, 13 out of 89 patients
with coexistent COPD and HF who received the drug
for at least 3 months could not tolerate it [87]. The rea-
sons for intolerance were not specified. Forty-three pa-
tients with HF and COPD with negative acute
bronchodilator test receiving carvedilol were followed
for a mean of 2.4 years and only 1 patient did not toler-
ate carvedilol because of COPD exacerbation [88]. In
contrast, only 50 % of 12 patients with asthma tolerated
carvedilol [88] (Table 2). In one study of 63 (Table 2)
elderly patients with mild to moderate HF and moderate
to severe COPD, patients were randomized to bisprolol
or carvedilol. While only in one patient of the carvedilol
group the study medication had to be withdrawn be-
cause of wheezing, there were no differences between
groups in the number of patients in which the BB had to
be suspended (3 each) [89]. FEV1 significantly increased
in bisoprolol (~130 ml) but not carvedilol (~30 ml) [89].
A randomized, open label, crossover trial involving 51
subjects receiving optimal therapy for HF (Table 2) ex-
amined the effects of switching baseline BB treatment to
carvedilol, metoprolol or bisoprolol for 6 weeks before
resuming their original BB. Of the 51 subjects, thirty
-five had coexistent mild to moderate COPD. In them
FEV1 was lowest with carvedilol and highest with biso-
prolol (~150 ml or 8 % of difference). Response to salbu-
tamol was tested in 53 HF patients on background BB
therapy and it was significantly higher in patients on
bisoprolol as compared to carvedilol (p = 0.04) [90].
In summary the available evidence suggest that the
third generation non-selective BB produce demonstrable
changes in airway function in patients with COPD and
tend to worsen airflow obstruction more than beta1 se-
lective agents.
Post-hoc analysis of prospective studies
The analysis of COPD populations included in large
studies on the use BB with HF [91, 92] show a pro-
tective effect comparing those on BB with those not
using them [60].
Cohort and administrative database studies
Two meta-analysis of cohort studies have shown a pro-
tective effects of BB in patients with COPD and con-
comitant use of BB for CAD, HF or other reasons RR
0.69 (0.62–0.78) [93] and 0.72 (0.63 to 0.83) [94] respect-
ively. A protective effect on the development of exacer-
bations was also observed in one of them [94]. Among
3834 residents of Alberta, Canada, aged 65 years or
older, diagnosed with COPD who had at least one
hospitalization for heart failure between April 1, 1994,
and March 31, 1998 included in the Canadian Institute
for Health Information database and followed a median
of 21 month (Table 3), those on BB (n = 242) showed
lower risk of all causes mortality (HR = 0.78, 0.63–0.95)
[95]. In a cohort of 1966 patients (66 ± 11 years) enrolled
in general internal medicine clinics at seven Veterans
Affairs medical centers between December 1996 and Oc-
tober 1999, Those who had a diagnosis of both COPD
and hypertension and were receiving single-agent anti-
hypertensive therapy were studied (Table 3). Compared
with calcium channel blockers, BB were associated with
a decrease in mortality from any cause after adjusting
for other risk factors (HR = 0.57, 0.33–0.89). The associ-
ation was similar when beta-blockers were compared
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with several other antihypertensive medications and was
independent of whether the patient had a pre-existing
cardiac disease [96]. The medical records of 41,814
COPD patients (22 % on BB) and 3819 asthmatics (17 %
on BB) with myocardial infarction were abstracted by
the Cooperative Cardiovascular Project, which was spon-
sored by the Health Care Financing Administration for
Medicare payment [20] (Table 3). BB treatment reduced
the 2-yr mortality (OR = 0.60, 0.57–0.63) similarly than
in the non-COPD population [20]. A different analysis
the same database included 54,962 with acute myocar-
dial infarction as main discharge diagnosis and with
COPD or asthma (defined by an established diagnosis
previous to the admission or prescription respiratory
medication in the medical records) (Table 3). Both re-
spiratory conditions were pooled together for the ana-
lysis and patients were stratified according to severity
based on the use of medication (yes or not ≥1
Table 2 Clinical trials that have addressed the effect of beta-blockers on clinical of functional pulmonary outcomes in patients with
concomitant cardiac and obstructive respiratory conditions
Population/design n Drug (mean daily dose) Follow-
up
Outcomes
Hawkins et al. [82] HF with moderate COPD/
randomized, controlled,
double-blinded
27 (14/13) Bisoprolol (7.3 mg) vs
placebo
4 month FEV1 significantly decreased
(−70 vs. +120 ml)
SF-36↑ n.s. 2.6 vs 0.5
No increase in exacerbations




Carvedilol 2.4 year In 1 COPD (3 %) and 3 asthmatics
(25 %) the drug had to be withdraw
because of worsening of the respiratory
condition
(29 mg COPD/19 mg
asthma)
Lainscak et al. [89] Elderly HF with moderate
COPD/randomized,
controlled, open-label




1 patient of the carvedilol group had to
be withdrawn because of “wheezing”, no
differences between groups in the number
of patients in which the BB had to be
suspended (3 each). FEV1 significantly




HF with moderate COPD/
randomized, open label,
triple-crossover
35 Bisoprolol vs metoprolol vs
carvedilol equivalent dose
but mean not specified
6 month FEV1 ~ 150 ml or 8 % higher with bisoprolol
and metoprolol than with carvedilol
Camrari et al. [92] CAD with moderate to severe
COPD/quasi-experimental
50 Metoprolol 3 month No change in FEV1
(93 mg CR or 189 mg
conventional)
No adverse events
Dorow et al. [91] CAD with moderate COPD/
randomized, double-blind
crossover
40 Atenolol (50 mg) vs
bisoprolol (5 mg)
6 month FEV1 declined significantly (~0.2 l) in both
treatment arms.
(20/20)
FEV1 forced expiratory volume in the first second; HF heart failure; CAD Coronary artery disease; COPD chonic obstructive lung disease; n.s. non-significant; SF-36;
Shor form health survey questionnaire
Table 3 Association between beta-blockers and all–cause mortality in patients with chronic obstructive lung disease in observational
studies
Population n with COPD Follow-up Adjusted risk (95 % CI)
Sin et al. [95] Heart failure 3834 median 21 month 0.78 (0.63–0.95)
Hawkins et al. [91] Heart failure 1258 median 25 month 0.74 (0.68–0.80)
Gottlieb et al. [20] Myocardial infarction 41,814 2 years 0.60 (0.57–0.63)
Chen et al. [97] Myocardial infarction 10,988 1 year 0.86 (0.73–1.00)
Van Gestel et al. [112] Vascular disease 1205 median 5 years 0.73 (0.60–0.88)
Au et al. [96] Hypertension 1966 2 years 0.57 (0.33–0.89)
Rutten et al. [99] COPD primary care 2230 7.2 years 0.68 (0.56–0.83)
Lee at al. [102] Multiple conditions 1062 median 44 months 0.87 (0.67-1.13)
Dransfield et al. [103] COPD exacerbation 825 — 0.39 (0.14–0.99)
Stefan et al. [104] COPD exacerbation 10,174 — 088 (0.71–1.09)
Short et al. [101] COPD primary care 5977 4.3 years 0.78 (0.67–0.92)
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prescription of oral corticosteroids or ≥1 admission the
previous year). While BB showed a protective effect
in those with mild/moderate COPD or asthma, no
survival benefit (No harm either) was found with BB
in the elderly and those with severe pulmonary dis-
ease [97]. As adherence to treatment was not avail-
able it is possible that those older or sicker could not
take the BB as prescribed. In a retrospective observa-
tional cohort study 11,592 adult patients registered in
the General Electric Centricity electronic medical rec-
ord database with a diagnosis of asthma and/or
COPD identified from August 1, 1997 to December
31, 2005 who were taking BB for at least 30 days
were compared with patients who had never received
BB (controls) (Table 3). Of these patients, 3062 were
on cardio-selective and 690 on non-selective BB; 7840
were controls. While in patients with asthma, BB,
particularly the non-selective ones, increased the risk
of admission or visits to the emergency department,
in patients with COPD alone, beta1-selective BB had
a protective effect for hospitalizations, RR = 0.64
(0.43–0.96) while non-selective BB had not (RR 1.02,
0.52–2.02) [98]. In the Utrecht General Practitioners
Network Database (Table 3), 2230 patients were iden-
tified who were older than 45 years with a diagnosis
of COPD between 1996 and 2006. During a mean
follow-up of 7.2 (2.8) years, 686 patients (30.8 %) died
and 1055 (47.3 %) had at least 1 exacerbation of
COPD. BB had a protective effect for both outcomes
with adjusted hazard ratios of 0.68 (0.56–0.83) and
0.71 (0.60–0.83) respectively for mortality and exacer-
bations [99]. In a retrospective study of the Premier
Perspective database involving 56,394 patients admit-
ted with the diagnosis of COPD (Table 3), the all-
cause in-hospital mortality was 2.4 %. BB use had an
independent protective effect on in-hospital mortality
(RR = 0.76, 0.67–0.86) [100]. In a recent retrospective
cohort study in Scotland of 5996 COPD patients with
concomitant CAD, HF or other vascular diseases, an
overall 22 % reduction in all-cause mortality was seen
in those on BB therapy (88 % of the BB used were
cardio-selective) [101]. Furthermore, additive benefits
to BB were observed with any of the possible combi-
nations of inhaled therapy compared with controls
(receiving only inhaled therapy with short acting
bronchodilators) [101].
In partial contrast with the previous findings a re-
cent study of the 2004–2007 Medicare Current Bene-
ficiary Survey cohorts (a nationally representative
sample of Medicare beneficiaries) including 1062 eld-
erly patients (age = 77 ± 7 years) with COPD and CAD
(half with and half without BB), BB did not appear to
have any protective effect on cardiac events, pulmon-
ary events, or all-cause mortality (Table 3) [102]. In
this study specific factors of older people such as
functional and cognitive status were determinants of
receiving BB and of experiencing the outcomes and
may have influenced the results. In addition the sam-
ple size, while large, included much less patients than
the other studies mentioned above and there is the
possibility of a lack of statistical power to detect the
protective effects of BB. In any case it has to be
stressed that no harmful effect on respiratory events
was observed on the BB group.
Exacerbations
A relatively small retrospective study (n = 825) of the
administrative data from the University of Alabama
Hospital [60] suggested that BB use during exacerba-
tions reduced mortality (OR = 0.39, 0.14 to 0.99) [103]
(Table 3). In a much larger retrospective cohort study
(n = 35,082) of patients older than 40 years with CAD,
CHF or hypertension, who were hospitalized for an
acute exacerbation of COPD from the 1st of January,
2006 to the 1st of December, 2007 at 404 acute care
hospitals throughout the USA, 29 % were treated with
BB in the first two hospital days, including 22 % with
beta1-selective and 7 % with non-selective BB (Table 3)
[104]. There was no association between BB therapy and
in-hospital mortality (OR = 0.88, 0.71–1.09), 30-day re-
admission (OR = 0.96, 0.89–1.03) or late mechanical venti-
lation (OR = 0.98, 0.77–1.24). However, when compared
with beta1 selective BB, receiving non-selective BB’s was
associated with an increased risk of 30-day readmission,
OR = 1.25 (1.08 to 1.44) [104].
In another study 8390 individuals with a diagnosis of
asthma or COPD and receiving treatment with a BB or
another cardiovascular agent were identified in 2000–
2001 from three Veterans Administration databases in
Iowa and Nebraska (USA) (Table 3) [105]. The HR for
hospital admission for asthma or COPD during the ob-
servation year was not different for patients taking and
not taking BB and no difference was noted with selective
versus nonselective beta-blockers. Curiously enough, the
hospital admission rate was lower with atenolol than
metoprolol [105].
Considered together, the cumulative evidence from tri-
als observational studies and meta-analysis indicates that
selective beta1-blokers should not be withheld when
COPD coexists with cardiovascular diseases, because the
benefits for their cardiac conditions far outweigh the
risks [80, 106]. While cardio-selective agents cause less
functional impairment, beta-blockade with both selective
and non-selective agents, when required, beneficially im-
pacts mortality [20, 93, 94, 97, 99, 101]. Therefore,
current guidelines from the Heart Failure Society of
America recommend BB in all patients with coexistent
COPD and HF or CAD [106, 107].
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Current use of BB
In spite of the evidence in favor and guidelines recom-
mendations [106–109], the proportion of COPD patients
with indication for BB drugs because of a heart disease
who are actually on BB remains low [103, 108, 110–113].
In one recent study in Spain BB were prescribe in around
58 % of those COPD patients attended at specialized
COPD clinics in whom BB were indicated, while in
patients not believed to have COPD and managed by
cardiologist the rate was 97 %. This proportion may
be lower in the primary care settings [5]. While cau-
tion is needed when comparing information between
different situations and different countries, it appears
that there is a trend to increase the prescription of
BB in COPD patients who need them for cardiovas-
cular disease [5, 97, 110, 111, 114]; This is consistent
with the trend to an increasing use of BB in COPD
noticed in the Worcester (Massachusetts) Heart At-
tack Study cohort [115].
Some evidence suggests that to be effective in reducing
admissions, BB therapy must adequately control heart
rate (i.e. heart rate < 70 min−1) [113, 116].
The use of BB in patients with COPD and CHF can be
substantially and safely increased by a structured out-
patient program [117].
Conclusions
In summary, there is a bulk of evidence suggesting that
BB therapy is safe in COPD patients who need it for co-
existent cardiovascular diseases. Epidemiological evi-
dence suggested that its use reduces mortality and the
risk of exacerbations in general terms; Benefits are less
evident in those older or with more severe disease.
Therapy should be attempted with selective beta−1
adrenergic blockade, but if necessary patients with
concomitant stable mild to moderate COPD who do
not have reversible airway obstruction can tolerate
non-selective BB. Selective BB is recommended in pa-
tients with severe COPD or who have reversible air-
way obstruction. In these patients a close initial
monitoring and management by physicians with ex-
perience is recommend.
Observational evidence suggests that BB therapy does
not increase the risk of in-hospital mortality or late
mechanical ventilation during exacerbations; therefore it
is not necessary to routinely withdraw them during these
episodes.
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